Additionally, in an illuminating case report, denosumab, a RANKL-specific antibody for osteoporosis treatment, unexpectedly improved liver injury in an osteoporotic patient who had NASH simultaneously [21]. Here, TNFSF11 is linked to metabolic dysfunction-associated steatohepatitis.